List view / Grid view
The FDA has granted Breakthrough Therapy Designation for Tagrisso for the…
The FDA has granted Breakthrough Therapy Designation for Tagrisso for the 1st-line treatment of patients with NSCLC...
It has been announced that the FDA has awarded AstraZeneca’s…
It has been announced that the FDA has awarded AstraZeneca’s acalabrutinib product for MCL treatment Breakthrough Therapy Designation...
AstraZeneca and MedImmune, have today announced that the US Food…
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer...
The European Commission (EC) has granted full marketing authorisation for…
27 April 2017 | By Niamh Marriott, Junior Editor
The European Commission (EC) has granted full marketing authorisation for AstraZeneca’s Tagrisso (osimertinib) for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
AstraZeneca and Acerta Pharma have announced that the European Medicines…
AstraZeneca and Acerta Pharma have announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted three positive opinions recommending acalabrutinib (ACP-196) for designation as an orphan medicinal product.
